Switch theme
Sign up to access all valuation multiples
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
2009
619
LTM Revenue $196M
LTM EBITDA -$64.6M
$1.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Adaptive Biotech has a last 12-month revenue (LTM) of $196M and a last 12-month EBITDA of -$64.6M.
In the most recent fiscal year, Adaptive Biotech achieved revenue of $179M and an EBITDA of -$129M.
Adaptive Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Adaptive Biotech valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $196M | XXX | $179M | XXX | XXX | XXX |
| Gross Profit | $121M | XXX | $107M | XXX | XXX | XXX |
| Gross Margin | 62% | XXX | 60% | XXX | XXX | XXX |
| EBITDA | -$64.6M | XXX | -$129M | XXX | XXX | XXX |
| EBITDA Margin | -33% | XXX | -72% | XXX | XXX | XXX |
| EBIT | -$145M | XXX | -$155M | XXX | XXX | XXX |
| EBIT Margin | -74% | XXX | -87% | XXX | XXX | XXX |
| Net Profit | -$146M | XXX | -$159M | XXX | XXX | XXX |
| Net Margin | -74% | XXX | -89% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Adaptive Biotech's stock price is $10.
Adaptive Biotech has current market cap of $1.4B, and EV of $1.3B.
See Adaptive Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.3B | $1.4B | XXX | XXX | XXX | XXX | $-0.98 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Adaptive Biotech has market cap of $1.4B and EV of $1.3B.
Adaptive Biotech's trades at 7.5x EV/Revenue multiple, and -10.4x EV/EBITDA.
Equity research analysts estimate Adaptive Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Adaptive Biotech has a P/E ratio of -9.9x.
See valuation multiples for Adaptive Biotech and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| EV (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EV/Revenue | 6.8x | XXX | 7.5x | XXX | XXX | XXX |
| EV/EBITDA | -20.7x | XXX | -10.4x | XXX | XXX | XXX |
| EV/EBIT | -9.2x | XXX | -8.6x | XXX | XXX | XXX |
| EV/Gross Profit | 11.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -9.9x | XXX | -9.0x | XXX | XXX | XXX |
| EV/FCF | -33.1x | XXX | -13.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAdaptive Biotech's last 12 month revenue growth is 22%
Adaptive Biotech's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.4M for the same period.
Adaptive Biotech's rule of 40 is -90% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Adaptive Biotech's rule of X is 21% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Adaptive Biotech and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 22% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Margin | -33% | XXX | -72% | XXX | XXX | XXX |
| EBITDA Growth | -62% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -90% | XXX | -50% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 21% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 47% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 58% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 147% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Zomedica | XXX | XXX | XXX | XXX | XXX | XXX |
| AnteoTech | XXX | XXX | XXX | XXX | XXX | XXX |
| Proteomics International | XXX | XXX | XXX | XXX | XXX | XXX |
| Biohit | XXX | XXX | XXX | XXX | XXX | XXX |
| Genomictree | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Adaptive Biotech acquired XXX companies to date.
Last acquisition by Adaptive Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Adaptive Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Adaptive Biotech founded? | Adaptive Biotech was founded in 2009. |
| Where is Adaptive Biotech headquartered? | Adaptive Biotech is headquartered in United States of America. |
| How many employees does Adaptive Biotech have? | As of today, Adaptive Biotech has 619 employees. |
| Who is the CEO of Adaptive Biotech? | Adaptive Biotech's CEO is Mr. Chad M. Robins. |
| Is Adaptive Biotech publicy listed? | Yes, Adaptive Biotech is a public company listed on NAS. |
| What is the stock symbol of Adaptive Biotech? | Adaptive Biotech trades under ADPT ticker. |
| When did Adaptive Biotech go public? | Adaptive Biotech went public in 2019. |
| Who are competitors of Adaptive Biotech? | Similar companies to Adaptive Biotech include e.g. Zomedica, AnteoTech, Proteomics International, Biohit. |
| What is the current market cap of Adaptive Biotech? | Adaptive Biotech's current market cap is $1.4B |
| What is the current revenue of Adaptive Biotech? | Adaptive Biotech's last 12 months revenue is $196M. |
| What is the current revenue growth of Adaptive Biotech? | Adaptive Biotech revenue growth (NTM/LTM) is 22%. |
| What is the current EV/Revenue multiple of Adaptive Biotech? | Current revenue multiple of Adaptive Biotech is 6.8x. |
| Is Adaptive Biotech profitable? | Yes, Adaptive Biotech is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Adaptive Biotech? | Adaptive Biotech's last 12 months EBITDA is -$64.6M. |
| What is Adaptive Biotech's EBITDA margin? | Adaptive Biotech's last 12 months EBITDA margin is -33%. |
| What is the current EV/EBITDA multiple of Adaptive Biotech? | Current EBITDA multiple of Adaptive Biotech is -20.7x. |
| What is the current FCF of Adaptive Biotech? | Adaptive Biotech's last 12 months FCF is -$40.3M. |
| What is Adaptive Biotech's FCF margin? | Adaptive Biotech's last 12 months FCF margin is -21%. |
| What is the current EV/FCF multiple of Adaptive Biotech? | Current FCF multiple of Adaptive Biotech is -33.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
